EIF1AX mutations have been detected at low frequency in a variety of cancer types reported in the TCGA studies (1.6% endometrial carcinoma, 1.5% thyroid carcinoma, 1.4% low grade glioma, 1.3% lung adenocarcinoma, 1.1% cutaneous melanoma (cBioPortal) [28]. Here, EIF1AX is linked to central nervous system cancer.